1ProLynx LOGO.png
ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors
January 24, 2024 09:00 ET | ProLynx LLC
SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper entitled “Could...
1ProLynx LOGO.png
ProLynx announces publication and initiation of patient recruitment for a trial of once-monthly treatment of diabetes in cats
September 05, 2019 09:00 ET | ProLynx LLC
SAN FRANCISCO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Today, ProLynx announced publication of data supporting therapy of Type 2 diabetes in cats with PLX039, a GLP-1 receptor agonist that can be...
1ProLynx LOGO.png
ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye
May 02, 2019 06:00 ET | ProLynx LLC
SAN FRANCISCO, May 02, 2019 (GLOBE NEWSWIRE) -- Today ProLynx LLC announced a second collaboration with Daiichi Sankyo Company, Limited to utilize its drug delivery linker technology to extend the...
1ProLynx LOGO.png
ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye
August 29, 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for...
1ProLynx LOGO.png
ProLynx extends lead in half-life extension platform technology – Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
April 03, 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, April 03, 2018 (GLOBE NEWSWIRE) -- ProLynx announced today the publication of a paper demonstrating its leading capabilities to exploit primary deuterium kinetic isotope effects...
1ProLynx LOGO.png
ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
September 25, 2017 09:00 ET | ProLynx LLC
SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control...